| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.15 | 0.0003 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.16 | 0.0008 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.14 | 0.002 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.14 | 0.006 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.12 | 0.007 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.098 | 0.03 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.094 | 0.05 |